Fig 6.tif (4.06 MB)
Download fileExperimental results from the USPIO MRI study.
figure
posted on 2017-04-27, 18:57 authored by Hasan Alsaid, Tinamarie Skedzielewski, Mary V. Rambo, Kristen Hunsinger, Bao Hoang, William Fieles, Edward R. Long, James Tunstead, Danielle J. Vugts, Matthew Cleveland, Neil Clarke, Christopher Matheny, Beat M. JuckerNo difference in body weight (A) was observed between groups. Tumor growth (B) was significantly inhibited in the GSK2849330 treated group (red) compared to the vehicle group (black). **p<0.01, ***p<0.001 using 2 way ANOVA. Axial MRI slices (C) showing T2*-w images pre-USPIO and 24 hours post injection of ferumoxytol (Post-USPIO). Red arrows indicate xenograft tumor location. Tumor signal/noise ratio (S/N (T2*-w)) decreased significantly post-USPIO injection in the GSK2849330 treated group (red bars). However, no difference was found in the vehicle group (D). Data is presented as mean±SEM (S4 Table). **p<0.01: Unpaired t-test (two-tailed).
History
Usage metrics
Read the peer-reviewed publication
Categories
Keywords
tumor dose responseImmuno-PET biodistribution imagingHER 3 ADCCCHLtime course dataMRIsupport dose optimizationHER 3 receptor occupancyxenograft tumorstumor uptakeGSK 2849330 co-injectedHER 3 mAbtumor macrophage contentGSK 2849330 dispositionex-vivo confocal microscopyBxPC 3 xenograft tumorUSPIOCDCHER 3xenograft tumor-bearing miceradiolabeled 89 Zr-GSK 2849330cytoplasmic punctate staining patternbody drug biodistributionGSK 2849330144 hours post injectionGSK 2849330 biodistribution89 Zr-GSK 2849330. In-vivo NIRFxenograft tumor uptake89 Zr-GSK 2849330.tumor macrophage recruitment
CC BY 4.0